Faculty Opinions recommendation of Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.13931968.15696056 ◽

2012 ◽

Author(s):

Mellar Davis

Keyword(s):

Ovarian Cancer ◽

Advanced Ovarian Cancer ◽

Malignant Ascites ◽

Controlled Study ◽

Phase 2 ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Faculty Opinions recommendation of Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.13931968.15387072 ◽

2012 ◽

Author(s):

Michael Fisch

Keyword(s):

Ovarian Cancer ◽

Advanced Ovarian Cancer ◽

Malignant Ascites ◽

Controlled Study ◽

Phase 2 ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study

The Lancet Oncology ◽

10.1016/s1470-2045(11)70338-2 ◽

2012 ◽

Vol 13 (2) ◽

pp. 154-162 ◽

Cited By ~ 92

Author(s):

Walter H Gotlieb ◽

Frederic Amant ◽

Suresh Advani ◽

Chanchal Goswami ◽

Hal Hirte ◽

...

Keyword(s):

Ovarian Cancer ◽

Advanced Ovarian Cancer ◽

Malignant Ascites ◽

Controlled Study ◽

Phase 2 ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

A phase 2, randomized, double-blind, placebo- controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer: a Gynecologic Oncology Group partners study

Annals of Oncology ◽

10.1093/annonc/mdx049 ◽

2017 ◽

Vol 28 (5) ◽

pp. 996-1004 ◽

Cited By ~ 30

Author(s):

B.J. Monk ◽

M.F. Brady ◽

C. Aghajanian ◽

H.A. Lankes ◽

T. Rizack ◽

...

Keyword(s):

Ovarian Cancer ◽

Liposomal Doxorubicin ◽

Gynecologic Oncology ◽

Pegylated Liposomal Doxorubicin ◽

Controlled Study ◽

Gynecologic Oncology Group ◽

Phase 2 ◽

Oncology Group ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Faculty Opinions recommendation of Elagolix treatment for endometriosis-associated pain: results from a phase 2, randomized, double-blind, placebo-controlled study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718047281.793481249 ◽

2013 ◽

Author(s):

Jim Tsaltas

Keyword(s):

Controlled Study ◽

Phase 2 ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study

The Lancet Respiratory Medicine ◽

10.1016/s2213-2600(17)30305-3 ◽

2017 ◽

Vol 5 (10) ◽

pp. 785-794 ◽

Cited By ~ 79

Author(s):

Hossein-Ardeschir Ghofrani ◽

Gérald Simonneau ◽

Andrea M D'Armini ◽

Peter Fedullo ◽

Luke S Howard ◽

...

Keyword(s):

Pulmonary Hypertension ◽

Chronic Thromboembolic Pulmonary Hypertension ◽

Controlled Study ◽

Phase 2 ◽

Double Blind ◽

Double Blind Placebo ◽

Multicentre Phase ◽

Thromboembolic Pulmonary Hypertension

Download Full-text

Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(21)00531-3 ◽

2021 ◽

Author(s):

Susana Banerjee ◽

Kathleen N Moore ◽

Nicoletta Colombo ◽

Giovanni Scambia ◽

Byoung-Gie Kim ◽

...

Keyword(s):

Ovarian Cancer ◽

Brca Mutation ◽

Advanced Ovarian Cancer ◽

Newly Diagnosed ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

P.577 ADVANCE: phase 2, randomised, double-blind, placebo-controlled study of adjunctive pimavanserin in patients with negative symptoms of schizophrenia

European Neuropsychopharmacology ◽

10.1016/j.euroneuro.2020.09.423 ◽

2020 ◽

Vol 40 ◽

pp. S328-S329

Author(s):

D. Bugarski-Kirola ◽

C. Arango ◽

M. Fava ◽

H. Nasrallah ◽

I.Y. Liu ◽

...

Keyword(s):

Negative Symptoms ◽

Controlled Study ◽

Phase 2 ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Phase 2, Randomized, Double-Blind, Placebo Controlled Study of Inecaclcitol Combined with Decitabine versus Decitabine: A New Treatment Strategy for Elderly AML Patients Unfit for Intensive Chemotherapy

Clinical Lymphoma Myeloma & Leukemia ◽

10.1016/j.clml.2017.07.059 ◽

2017 ◽

Vol 17 ◽

pp. S279

Author(s):

Olivier Hermine ◽

Jean Francois Dufour-Lamartinie ◽

Stephanie Renaux ◽

Jorge Cortes

Keyword(s):

Treatment Strategy ◽

Controlled Study ◽

Intensive Chemotherapy ◽

Phase 2 ◽

Double Blind ◽

Double Blind Placebo ◽

Elderly Aml ◽

New Treatment

Download Full-text

JKB-122 in subjects with non-alcoholic fatty liver disease (NAFLD): a phase 2, randomized, multiple-dose, double-blind, placebo-controlled study

Journal of Hepatology ◽

10.1016/s0168-8278(20)30779-0 ◽

2020 ◽

Vol 73 ◽

pp. S133

Author(s):

Kuo-Chin Huang ◽

Ming-Yao Chen ◽

Chih-Lin Lin ◽

Sien-Sing Yang ◽

Chao-Wei Hsu ◽

...

Keyword(s):

Liver Disease ◽

Fatty Liver ◽

Fatty Liver Disease ◽

Multiple Dose ◽

Controlled Study ◽

Phase 2 ◽

Double Blind ◽

Alcoholic Fatty Liver ◽

Double Blind Placebo ◽

Alcoholic Fatty Liver Disease

Download Full-text

OP0019 Baricitinib in systemic lupus erythematosus (SLE): results from a phase 2, randomised, double-blind, placebo-controlled study

10.1136/annrheumdis-2018-eular.1918 ◽

2018 ◽

Cited By ~ 1

Author(s):

D.J. Wallace ◽

R.A. Furie ◽

Y. Tanaka ◽

K.C. Kalunian ◽

M. Mosca ◽

...

Keyword(s):

Systemic Lupus Erythematosus ◽

Lupus Erythematosus ◽

Controlled Study ◽

Phase 2 ◽

Systemic Lupus ◽

Double Blind ◽

Double Blind Placebo

Download Full-text